The aim was to evaluate sentinel node detection capacity by means of a magnetic probe in 11 patients with oral squamous cell carcinoma at stages T1-T2 received submucosal injections of a superparamagnetic iron oxide contrast agent (SPIO). A magnetic probe was used for sentinel node biopsy. The use of SPIO and magnetic probes in the early stages of oral cancer may offer an alternative to conventional radioisotope techniques and/or elective neck dissection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jso.25810 | DOI Listing |
Hum Vaccin Immunother
December 2025
Institute of Pathological Anatomy, Faculty of Medicine, Comenius University in Bratislava and University Hospital in Bratislava, Bratislava, Slovakia.
Considering the increasing use of immune checkpoint inhibitors in cancer treatment, our aim is to report a rare cutaneous immune-related adverse event induced by PD-1 inhibitor pembrolizumab and provide a brief overview of pembrolizumab-induced subacute cutaneous lupus erythematosus (SCLE) cases in the literature. We report a 67-year-old woman with oropharyngeal squamous cell carcinoma who developed SCLE during treatment with pembrolizumab. After 18 weeks (sixth cycle) of pembrolizumab immunotherapy, a widespread pruritic erythematous rash evaluated as grade 3 immune-related adverse event appeared primarily on the patient's limbs.
View Article and Find Full Text PDFOral Dis
January 2025
Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Background: This study aimed to investigate potential cellular senescence inhibitory genes (CSIGs) and discover novel therapeutic targets in head and neck squamous cell carcinoma.
Methods: Dysregulated CSIGs were identified based on The Cancer Genome Atlas (TCGA) and the Human Aging Genomic Resources (HAGR) database. Prognostic value and immune infiltration were assessed through bioinformatic analysis.
Front Med (Lausanne)
January 2025
Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Tongji Research Institute of Stomatology, Department of Prosthodontics, Shanghai Tongji Stomatological Hospital, Dental School, Tongji University, Shanghai, China.
Background: The conventional treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) is surgery; however, the efficacy of definitive chemoradiotherapy (CRT) remains controversial.
Objective: This study aimed to evaluate the ability of deep learning (DL) models to identify patients with LA-HNSCC who can achieve organ preservation through definitive CRT and provide individualized adjuvant treatment recommendations for patients who are better suited for surgery.
Methods: Five models were developed for treatment recommendations.
Cureus
December 2024
Oral and Maxillofacial Surgery, ITS Dental College, Hospital and Research Centre, Greater Noida, IND.
Introduction The role of concomitant chemoradiation therapy (CTRT) or radiation therapy (RT) is not well defined in operated cases of oral squamous cell carcinoma (OSCC) with positive perineural spread. The purpose of the study was to determine whether the use of concurrent CTRT or RT would enhance the five-year disease-free survival of patients with positive perineural invasion (PNI). Materials and methods Data were analysed retrospectively from January 2014 to December 2023.
View Article and Find Full Text PDFCase Rep Dent
January 2025
Department of Conservative Dentistry and Endodontics, College of Dental Surgery, B.P. Koirala Institute of Health Sciences, Dharan, Nepal.
Pleomorphic adenoma (PA), the most common salivary gland tumor, presents unique challenges due to its diverse clinicopathologic features. The objective of this case series is to highlight the implication of detailed histopathological examination to guide appropriate diagnosis. This study reviews 10 cases of PA diagnosed at B.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!